Table 2.
Univariate and multivariate Cox regression analyses of the impact on breast cancer-specific survival and recurrence-free survival for different patient and tumor characteristics
| Variable | Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|---|
| n | HR | 95 % CI | p | n | HR | 95 % CI | p | |
| Survival (CSS) | ||||||||
| FI (weak vs. strong) | 129 | 3.4 | 1.4–8.2 | 0.006 | 111 | 2.8 | 1.0–7.5 | 0.048 |
| ER (negative vs. positive) | 144 | 0.2 | 0.1–0.5 | 0.001 | 111 | 0.9 | 0.3–2.7 | 0.823 |
| HER2 (weak vs. strong) | 139 | 7.7 | 3.0–19.8 | <0.001 | 111 | 5.8 | 1.7–20.0 | 0.006 |
| NHG (1, 2, 3) | 144 | 5.1 | 2.0–13.0 | <0.001 | 111 | 1.1 | 0.3–4.0 | 0.923 |
| Size (≤20 vs. >20 mm) | 144 | 3.0 | 1.2–7.8 | 0.020 | 111 | 3.3 | 0.9–12.8 | 0.080 |
| Ki-67 (≤25 vs. >25 %) | 123 | 4.2 | 1.4–12.5 | 0.010 | 111 | 3.0 | 0.7–12.6 | 0.137 |
| Recurrence-free survival | ||||||||
| FI (weak vs. strong) | 130 | 4.4 | 2.0–9.4 | <0.001 | 127 | 3.4 | 1.5–7.4 | 0.002 |
| ER (negative vs. positive) | 144 | 0.3 | 0.1–0.6 | <0.001 | 127 | 0.8 | 0.3–2.0 | 0.577 |
| HER2 (weak vs. strong) | 139 | 7.1 | 3.0–16.9 | <0.001 | 127 | 5.7 | 2.3–14.5 | <0.001 |
| NHG (1, 2, 3) | 144 | 3.2 | 1.6–6.2 | <0.001 | 127 | 1.6 | 0.7–3.4 | 0.287 |
| Size (<20 vs. >20 mm) | 144 | 3.1 | 1.4–7.1 | 0.006 | 127 | 2.3 | 1.0–5.7 | 0.067 |
FI score was dichotomized into weak (value 0, 1, 2) and strong (3)
HR hazard ratio, CI confidence interval